Depakene and Broken bone - a phase IV clinical study of FDA data

Summary:

Broken bone is reported as a side effect among people who take Depakene (valproic acid), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Tegretol, and have Frontal lobe epilepsy.

The phase IV clinical study analyzes which people have Broken bone when taking Depakene. It is created by eHealthMe based on reports of 14,611 people who have side effects when taking Depakene from the FDA, and is updated regularly.

What is Depakene?

Depakene has active ingredients of valproic acid. It is often used in epilepsy. eHealthMe is studying from 14,776 Depakene users. Check the latest studies of Depakene.

What is Broken bone?

Broken bone is found to be associated with 1,304 drugs and 1,490 conditions by eHealthMe. Check the latest studies of Broken bone.

On Jul, 14, 2026

14,611 people reported to have side effects when taking Depakene.
Among them, 17 people (0.12%) have Broken bone.

Among these 17 people:

How long have people been on Depakene when they have Broken bone? *

What is the gender of people who have Broken bone when taking Depakene? *

female: 46.67 %
male: 53.33 %

What is the age of people who have Broken bone when taking Depakene? *

What are other drugs people take besides Depakene? *

What are other side effects people have besides Broken bone? *

Osteoporosis (bones weak and more likely to break): 3 people, 17.65%
Road Traffic Accident: 3 people, 17.65%
Ovarian Cysts (fluid filled sacs of the ovary): 2 people, 11.76%
Fever: 2 people, 11.76%
Drowsiness: 2 people, 11.76%
Nausea And Vomiting: 2 people, 11.76%
Nausea (feeling of having an urge to vomit): 2 people, 11.76%
Pain: 2 people, 11.76%
Eye Movement Disorder: 2 people, 11.76%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 11.76%

What are the existing conditions these people have? *

Sedation: 2 people, 11.76%
Idiopathic Generalised Epilepsy (epileptic disorders that are believed to have a strong underlying genetic basis): 2 people, 11.76%
Frontal Lobe Epilepsy (recurring seizures that arise in the frontal lobes of the brain): 2 people, 11.76%
Transient Ischaemic Attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)): 1 person, 5.88%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 5.88%
Partial Seizures (seizures which affect only a part of the brain at onset): 1 person, 5.88%
Parkinson's Disease: 1 person, 5.88%
Osteoporosis (bones weak and more likely to break): 1 person, 5.88%
Osteopenia (a condition where bone mineral density is lower than normal): 1 person, 5.88%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Depakene and have Broken bone?

- Check whether Broken bone is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Depakene:

Depakene (14,776 reports)

Broken bone treatments and more:

Broken bone (35,552 reports)

Browse all side effects of Depakene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Broken bone:

Broken bone (1,304 drugs)

Browse all the conditions that are associated with Broken bone:

Broken bone (1,490 conditions)

Related publications that referenced our studies

Gupta E, Kunjal R, Cury JD, "Severe hyponatremia due to valproic acid toxicity", Journal of clinical medicine research, 2015 Jan .
Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, "Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study", journal of surgical research, 2014 Jan .
Gupta E, Kunjal R, Cury JD, "Severe hyponatremia due to valproic acid toxicity", Journal of clinical medicine research, 2015 Jan .
Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, "Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study", journal of surgical research, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on valproic acid (the active ingredients of Depakene) and Depakene (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.